Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
PEGPH20 in addition to Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Ductal Adenocarcinoma	Gemcitabine (Gemzar; gemcitabine hydrochloride) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Pegvorhyaluronidase alfa (PEGPH20)	Pancreatic cancer	Gastrointestinal Cancer	2018	View \| Download
Pembrolizumab (Keytruda) for relapsed/refractory classical Hodgkin lymphoma	Pembrolizumab (Keytruda; MK-3475)	Hodgkin lymphoma	Haematological Cancer and Lymphomas	2018	View \| Download
Pembrolizumab for Advanced Hepatocellular Carcinoma – second line onwards	Pembrolizumab (Keytruda; MK-3475)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2018	View \| Download
Pembrolizumab for Stage IV Colorectal Carcinoma – first line	Pembrolizumab (Keytruda; MK-3475)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2018	View \| Download
Pembrolizumab in addition to chemotherapy for advanced or metastatic urothelial cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Urothelial cancer	Urological Cancer	2018	View \| Download
Pembrolizumab in addition to Chemotherapy for Locally Advanced, Non-Metastatic Triple Negative Breast Cancer – neoadjuvant, first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to chemotherapy for locally recurrent, inoperable or metastatic triple-negative breast cancer - first line	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2018	View \| Download
Pembrolizumab in addition to standard of care chemotherapy for extensive stage small cell lung cancer – first line	Pembrolizumab (Keytruda; MK-3475)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2018	View \| Download
Pembrolizumab in combination with Axitinib for Metastatic Renal Cell Carcinoma – first line	Axitinib (Inlyta; AG-013736) , Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2018	View \| Download
Pembrolizumab in Combination with Epacadostat for Unresectable or Metastatic Melanoma	Epacadostat (INCB024360) , Pembrolizumab (Keytruda; MK-3475)	Melanoma	Skin Cancer	2018	View \| Download